Good things are worth waiting for - welcome to the second half of 2022!
We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that will investigate the postoperative analgesic efficacy of CT001.We obtained regulatory approval by the authorities and thereby green light at the end of June and have since then prepared the site and involved dental clinics. We are ready and hope to announce first patient within a few weeks. This will basically take the company to the next level as not that many companies are in a late-stage clinical development...Upcoming top line results of Trial 0206